ProShares Trust - ProShares Investment Grade-Interest Rate Hedged
IGHG
Get informed when a big investor buys or sells
+ FollowShare Statistics
| Market cap | $27.84 Billion |
|---|---|
| Enterprise Value | $27.66 Billion |
| Dividend Yield | $4.01 (5.10%) |
| Earnings per Share | $- |
| Beta | -0.04 |
| Outstanding Shares | - |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2118.55 |
| Enterprise Value to EBIT | -368.05 |
| Enterprise Value to Net Income | -393 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 53.26%▲ 0.70% |
|---|---|
| Total Invested | $145.06M▼ 4.06% |
| Investors Holding | 59▼ 5.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...
Relevant Senate Committees
Controls tax policy (affecting profitability and R&D credits) and entitlement spending (Medicare/Medicaid), which directly determines drug reimbursement and market access for future approved products.
Directly allocates federal spending to agencies like the FDA, NIH, and VA, profoundly impacting the regulatory environment, research funding, and potential future sales for biopharmaceutical companies.
Directly regulates the FDA (drug approval, clinical trials) and NIH (research funding), which are existential to a clinical-stage biopharmaceutical company's operations and future products.
Has direct oversight over intellectual property laws (patents), which are fundamental for a biopharmaceutical company's competitive advantage and valuation, and antitrust enforcement.
Directly investigates issues affecting older Americans, a key demographic for BioAge's obesity drug in older adults, creating potential for significant headline risk regarding drug pricing and access.